Objective:To evaluate the efficiency of Epstein-Bar viral serology in detecting nasopharyngeal carcinoma(NPC)and comparing the NPC risks between serology-positive and serology-negative subjects.MethidsLUnnybiebztnatuc...Objective:To evaluate the efficiency of Epstein-Bar viral serology in detecting nasopharyngeal carcinoma(NPC)and comparing the NPC risks between serology-positive and serology-negative subjects.MethidsLUnnybiebztnatuc tutratuib for VCA-IgA was performed in 42048 subjects between the ages of 30 and 59.The titre of VCA-IgA,≥1/5,EA-IgA,≥1/5 was recognized as being positive.All those were followed up to the end of 1999.Results:45 NPCs were detected in the first year(45/42048,107.02/10^5).The average annual incidence of NPC in 3050 VCA-IgA-positive subjects(144.86/10^5)was higher than that(11.98/10^5)in 38953 VCA-IgA-negative subjects during the next 12 years.72 out the 154 NPC patients detected were of stage-I.Conclusion :This reveals that EBV serology could actually detect early-stage NPCs as previously reported.Meaningfully,the NPC risk increased 12 times the VCA-IgA-negative subjects in the VCA-IgA-positive subjects after the first-turn serological screening.The 5-year and 10-year survival rates of stage-I NPC patients(81.25%,67.39% respectively)were both significantly higher than those of the stage-II A, stage-II B and stage-Ⅲ patients (60.32%,26.67% respectively)after radiotherapy.展开更多
文摘Objective:To evaluate the efficiency of Epstein-Bar viral serology in detecting nasopharyngeal carcinoma(NPC)and comparing the NPC risks between serology-positive and serology-negative subjects.MethidsLUnnybiebztnatuc tutratuib for VCA-IgA was performed in 42048 subjects between the ages of 30 and 59.The titre of VCA-IgA,≥1/5,EA-IgA,≥1/5 was recognized as being positive.All those were followed up to the end of 1999.Results:45 NPCs were detected in the first year(45/42048,107.02/10^5).The average annual incidence of NPC in 3050 VCA-IgA-positive subjects(144.86/10^5)was higher than that(11.98/10^5)in 38953 VCA-IgA-negative subjects during the next 12 years.72 out the 154 NPC patients detected were of stage-I.Conclusion :This reveals that EBV serology could actually detect early-stage NPCs as previously reported.Meaningfully,the NPC risk increased 12 times the VCA-IgA-negative subjects in the VCA-IgA-positive subjects after the first-turn serological screening.The 5-year and 10-year survival rates of stage-I NPC patients(81.25%,67.39% respectively)were both significantly higher than those of the stage-II A, stage-II B and stage-Ⅲ patients (60.32%,26.67% respectively)after radiotherapy.
